|27.88||-1.58||-5.36%||Vol 1.33M||1Y Perf -39.20%|
|Oct 2nd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||62.36||Analyst Rating||Strong Buy 1.29|
|Potential %||123.67||Finscreener Ranking||★+ 44.45|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 40.03|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 40.73|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||-4.61||Earnings Rating||Strong Buy|
|Market Cap||2.68B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2023|
|Estimated EPS Next Report||-0.72|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.11M|
|Avg. Monthly Volume||794.55K|
|Avg. Quarterly Volume||733.80K|
Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 27.88 per share at the end of the most recent trading day (a -5.36% change compared to the prior day closing price) with a volume of 1.33M shares and market capitalization of 2.68B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.
The one-year performance of Cytokinetics Incorporated stock is -39.2%, while year-to-date (YTD) performance is -39.15%. CYTK stock has a five-year performance of 200.11%. Its 52-week range is between 28.96 and 52.4013, which gives CYTK stock a 52-week price range ratio of -4.61%
Cytokinetics Incorporated currently has a PE ratio of -13.80, a price-to-book (PB) ratio of 31.90, a price-to-sale (PS) ratio of 43.21, a price to cashflow ratio of 409.20, a PEG ratio of -, a ROA of -31.76%, a ROC of -39.38% and a ROE of -289.41%. The company’s profit margin is -99.17%, its EBITDA margin is -157.80%, and its revenue ttm is $92.63 Million , which makes it $0.98 revenue per share.
Of the last four earnings reports from Cytokinetics Incorporated, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.29), with a target price of $62.36, which is +123.67% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cytokinetics Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 9.79, ATR14 : 1.32, CCI20 : -138.05, Chaikin Money Flow : -0.33, MACD : -1.33, Money Flow Index : 11.39, ROC : -18.50, RSI : 26.33, STOCH (14,3) : 4.15, STOCH RSI : 0.00, UO : 31.17, Williams %R : -95.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: Blum Robert (Option Excercise at a value of $2 107 200), Blum Robert (Sold 230 000 shares of value $8 906 725 ), Blum Robert I (Option Exercise at a value of $120 625), Blum Robert I (Sold 12 500 shares of value $463 250 ), Ching W. Jaw (Sold 0 shares of value $-181 500 ), Ching W. Jaw (Sold 15 000 shares of value $675 000 ), Fady I. Malik (Option Excercise at a value of $319 040), Fady I. Malik (Sold 66 300 shares of value $2 783 546 ), Fady Ibraham Malik (Option Excercise at a value of $263 320), Fady Ibraham Malik (Sold 52 513 shares of value $2 250 634 ), Henderson John (Option Excercise at a value of $28 245), Henderson John (Sold 4 166 shares of value $157 350 ), Robert C. Wong (Sold 7 338 shares of value $321 607 ), Robert I. Blum (Option Excercise at a value of $988 013), Robert I. Blum (Sold 107 500 shares of value $4 475 995 ), Wendall Wierenga (Option Excercise at a value of $87 494), Wendall Wierenga (Sold 13 020 shares of value $507 760 ), Wendell D. Wierenga (Option Excercise at a value of $47 040), Wendell D. Wierenga (Sold 7 000 shares of value $315 000 ), Wong Robert (Sold 7 338 shares of value $321 607 )
Mon, 25 Sep 2023 11:00 GMT Analysts Top Healthcare Picks: Cytokinetics (CYTK), Amgen (AMGN)- TipRanks. All rights reserved.
Fri, 22 Sep 2023 10:31 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and CymaBay Therapeutics (CBAY)- TipRanks. All rights reserved.
Fri, 28 Jul 2023 20:05 GMT Cytokinetics (CYTK) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.